To investigate the consequences of BTK inhibition on tumor cells in vivo, we sequentially profiled the CLL transcriptome in 14 patients treated with single-agent ibrutinib (Supplementary Table 1). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.